-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On November 11, the CDE official website showed that the clinical application of GSK's new antibiotic Gepotidacin tablets was accepted by the State Food and Drug Administration
Gepotidacin is a first-in-class triazapyrene type II topoisomerase inhibitor.
Gepotidacin structure
In foreign countries, GSK has launched a Phase III clinical project of Gepotidacin for the treatment of uncomplicated urinary tract infections (uUTI) in October 2019
The second study (EGEL-2) was carried out in approximately 1,200 patients with uUTI.